Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

达必妥 - NMPA Drug Approval Details

Approvals/NMPA/Dupilumab Injection

Approved

生物制品

Dupilumab Injection

SANOFI-AVENTIS GROUPE🇨🇳 National Medical Products Administration

Approval Date: Sep 26, 2023
Approval ID: 8VIXz3Pn2c5
Company: SANOFI-AVENTIS GROUPE
Type: 生物制品

Approval Details

Approval Id: 8VIXz3Pn2c5
Approval Number: 国药准字SJ20235003
Generic Name: 度普利尤单抗注射液
Generic Name En: Dupilumab Injection
Trade Name: 达必妥
Drug Type: 生物制品
Dosage Form: 注射剂
Strength: 200mg（1.14mL）/支（预充式注射笔）
Reg Date: 2023-09-26
Expired Date: 2026-09-06
Company Name: SANOFI-AVENTIS GROUPE
Production Company Name: SANOFI WINTHROP INDUSTRIE
Company Detail Path: /organization/sanofi-aventis-groupe
Production Company Detail Path: /organization/sanofi-winthrop-industrie

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Sep 26, 2023

Approval ID

8VIXz3Pn2c5

Type

生物制品

Back to NMPA Approvals